A dual immunotherapy nanoparticle (DINP) conjugating anti‐PD‐1 Ab and T cells agonist antitumor necrosis factor receptor superfamily member 4 (aOX40) was developed to ensure that T cells could simultaneously bind the two agents.145 The DINP significantly elevated the rate of T cell activation and showed superior antitumor effect in B16F10 melanoma model and 4T1 breast cancer model compared with treatment with the two free antibodies. Here, PDCD1 is linked to melanoma.